Itraconazol Ratiopharm (Itraconazole)

• Itraconazole is used to manage fungal infections by targeting the ergosterol synthesis pathway.
• Systemic fungal infections: eradicates invasive pathogens such as Candida and Aspergillus species.
• Dermatophyte infections: clears skin, hair and nail infections caused by Trichophyton, Microsporum and Epidermophyton.
• Candida infections: treats oropharyngeal, esophageal and systemic candidiasis.
• Aspergillosis: controls chronic or invasive disease caused by Aspergillus spp.

• Itraconazole inhibits the fungal enzyme lanosterol 14α‑demethylase (CYP51), a key step in ergosterol biosynthesis. By blocking this enzyme, the drug reduces ergosterol content in the cell membrane, leading to increased membrane permeability and ultimately fungal cell death or growth inhibition.

Itraconazole may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Nausea or vomiting: mild gastrointestinal upset.
• Headache: transient cranial discomfort.
• Diarrhea: loose stools, usually self‑limiting.
• Abdominal pain: cramping or discomfort.
• Rash: mild skin irritation.
• Elevated liver enzymes: mild, reversible changes.

Serious or Rare Side Effects

• Hepatotoxicity: significant liver injury requiring monitoring.
• Congestive heart failure: fluid retention and reduced cardiac function.
• Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Visual disturbances: blurred vision or photophobia.
• Severe allergic reactions: anaphylaxis or angioedema.
• QT prolongation: cardiac arrhythmia risk in susceptible patients.

• Before initiating itraconazole therapy, consider patient‑specific factors and safety measures.
• Liver function: assess baseline hepatic enzymes and monitor periodically.
• Cardiac status: avoid in patients with existing heart failure or uncontrolled arrhythmias.
• Drug interactions: review concomitant medications for CYP3A4 substrates or inhibitors.
• Pregnancy and lactation: evaluate risk‑benefit, as safety data are limited.
• Renal impairment: adjust dosing only under medical supervision.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Itraconazole interacts with several drug classes, requiring careful management.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): markedly reduce itraconazole exposure.
• Certain antiarrhythmics (e.g., quinidine, amiodarone): increase risk of cardiac toxicity.
• HIV protease inhibitors (e.g., ritonavir): may cause unpredictable plasma levels.

Moderate Interactions (Monitor Closely)

• Statins metabolized by CYP3A4 (e.g., simvastatin, lovastatin): risk of myopathy.
• Oral anticoagulants (e.g., warfarin): may enhance anticoagulant effect.
• Benzodiazepines (e.g., midazolam, triazolam): increased sedation.
• Proton pump inhibitors: may affect absorption of itraconazole capsules.
• Digoxin: potential increase in serum concentrations.